Dynavax Technologies to Report First Quarter 2019 Financial Results and Host Conference Call on May 8
April 25 2019 - 4:05PM
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated
biopharmaceutical company focused on discovering and developing
novel vaccines and immuno-oncology therapeutics, will report its
first quarter 2019 financial results on Wednesday, May 8, 2019,
after the U.S. financial markets close.
Dynavax will host a conference call and live audio webcast on
Wednesday, May 8, 2019, at 4:30 p.m. (ET)/1:30 p.m. (PT).
The live audio webcast may be accessed through the "Events &
Presentations" page on the "Investors" section of the company's
website at www.dynavax.com. Alternatively, participants may dial
(855) 327-6837 (domestic) or (631) 891-4304 (international) and
refer to conference ID 10006654.
The archived conference call will be available on Dynavax’s
website beginning approximately two hours after the event and will
be archived and available for replay for at least 30 days after the
event.
About DynavaxDynavax is a fully-integrated
biopharmaceutical company focused on leveraging the power of the
body's innate and adaptive immune responses through toll-like
receptor (TLR) stimulation. Dynavax discovers and
develops novel vaccines and immuno-oncology therapeutics. The
Company launched its first commercial product, HEPLISAV-B®
[Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018,
following U.S. FDA approval for prevention of infection
caused by all known subtypes of hepatitis B virus in adults age 18
years and older. Dynavax's lead immunotherapy product,
SD-101, is an investigational cancer immunotherapeutic currently
being evaluated in Phase 1/2 studies and its second cancer
immunotherapeutic, DV281, is in Phase 1 development. For more
information, visit www.dynavax.com.
Contact:
ir@dynavax.com
510-665-7269
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024